OneSource Specialty Pharma Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xm2hnh3ckw192k8u3azqbsia.pdf

Key Takeaways


GLP-1: The Core Growth Engine

Neeraj Sharma: "Today you invest, the first revenue dollar comes back in 5 years. And by the time, as I said, we as pioneers have a significant headstart."

Biologics & Drug-Device: The Margin Story


Capacity & Capex: Scaling for the Opportunity

Arun Kumar: "We play the risk along with our partners jointly in the sense that we expect our partners to participate in capex or in reservation capacity fee. Consequently, we have that ability to take those decisions and that is why Anurag has articulated that capex should be from internal accruals because we don't need to borrow to build these capexes."

Financial Position & Balance Sheet


Commercial Model & Customer Dynamics

Neeraj Sharma: "I call it a fool's errand if I were to forecast where this market would be the way it is growing."

Operational Milestones & Governance


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue CAGR25% to 30% growthMedium term (3-4 years)
Revenue scaleINR40 crore companyNext 3-4 years
EBITDA margin40%Medium term (implied 3-4 years)
FY26 EBITDA marginWithin the range reported in Q3 FY25FY26
Capacity expansion5x increase from ~4 crore to ~22 crore unitsNext 3-4 years
Capex investmentINR10 croreNext 2-4 years
Debt-freeZero debtBefore end of FY27
Debt-to-EBITDALess than 1xMedium to long term
Revenue mix80% CSA, 20% MSASteady state (post-FY26)
Biologics commercializationFirst revenue from current Phase 3 asset3-4 years out
Balance sheet optimization planConcrete solutions presentedNext earnings call

Key Metrics

MetricQ3 FY25
Revenue₹392.6 cr, growth of about 18%
EBITDA₹143.2 cr, more than the previous two quarters combined
EBITDA margin36%
9-month revenuea little over ₹1,000 cr
9-month EBITDAabout ₹284 cr
Normalized EPS (fully diluted)₹7.8
Return on capital employedmid-30s range
Net debt₹581.7 cr, net of deposits and cash equivalents
Fundraise during the quarter₹801 cr, half used to retire high-cost debt
Medium-term revenue growth guidance25% to 30% CAGR
Medium-term revenue target₹40 cr revenue company in the next 3 to 4 years
Medium-term EBITDA margin target40%
Planned capex$100 million over the next 2 to 4 years
GLP-1 customers20
Total customers (logos)60-plus across all service offerings
GLP-1 cartridge capacity expansion5x, from 4 crore to almost 22 crore units in the next 3 to 4 years
MSA contracts signed in Q3more than in the full year FY24
Successful audits in 202436